IDEBENONE ( DrugBank: Idebenone )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	2
18	脊髄小脳変性症（多系統萎縮症を除く。）	3
113	筋ジストロフィー	37
302	レーベル遺伝性視神経症	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04152655 (ClinicalTrials.gov)	January 1, 2020	7/10/2019	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Idebenone;Drug: Placebo oral tablet	Second Affiliated Hospital, School of Medicine, Zhejiang University	Peking Union Medical College Hospital;Beijing Hospital;Beijing Tiantan Hospital;Xinhua Hospital, Sha ...	Recruiting	18 Years	N/A	All	180	Phase 2/Phase 3	China
2	NCT03727295 (ClinicalTrials.gov)	January 1, 2019	30/10/2018	Idebenone Treatment of Early Parkinson's Diseasesymptoms	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenonein the Treatment of Ea ...	Oxidative Stress is an Important Cause of Parkinson's Disease	Drug: Idebenone/placebo	Second Affiliated Hospital of Soochow University	Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	30 Years	80 Years	All	180	Phase 4	NULL

First Previous1Next Last

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04071639 (ClinicalTrials.gov)	March 12, 2020	26/8/2019	Symptomatic Therapy for Patients With Huntington's Disease	Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therap ...	Huntington Disease	Drug: Haloperidol 2Mg Tab;Drug: Risperidone 1Mg Tab;Drug: Zoloft 50Mg Tablet;Drug: Idebenone;Drug: D ...	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	N/A	N/A	All	60	Phase 1	China

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01854359 (ClinicalTrials.gov)	May 11, 2013	11/5/2013	Idebenone for Primary Progressive Multiple Sclerosis	Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis	Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Idebenone	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Unknown status	18 Years	N/A	All	61	Phase 1/Phase 2	United States
2	NCT00950248 (ClinicalTrials.gov)	November 1, 2009	30/7/2009	Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)	Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenonein Patients With Primary Progr ...	Primary Progressive Multiple Sclerosis	Drug: Idebenone;Other: placebo	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	65 Years	All	85	Phase 1/Phase 2	United States

First Previous1Next Last

18. 脊髄小脳変性症（多系統萎縮症を除く。）

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00229632 (ClinicalTrials.gov)	September 27, 2005	29/9/2005	Idebenone to Treat Friedreich's Ataxia	A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Effi ...	Friedreich Ataxia	Drug: Idebenone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	9 Years	17 Years	All	51	Phase 2	United States
2	NCT00078481 (ClinicalTrials.gov)	February 2004	27/2/2004	Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia	Phase 1B Clinical Trial to Establish the Safety and Tolerability of a Multiple-Dose Regimen of Idebe ...	Friedreich Ataxia	Drug: Idebenone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	16	Phase 1	United States
3	NCT00015808 (ClinicalTrials.gov)	May 2001	6/5/2001	Safety Study of Idebenone to Treat Friedreich's Ataxia	Phase I Clinical Trial to Establish the Maximum Tolerated Dose of Idebenonein Children, Adolescents, ...	Friedreich Ataxia	Drug: Idebenone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	100	Phase 1	United States

First Previous1Next Last

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

diseases per page:

Showing 1 to 10 of 37 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-000602-10-BG (EUCTR)	10/03/2020	07/01/2020	A clinical study to assess how effective and safe is idebenonetreatment in patients with Duchenne Mu ...	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and To ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;Spain;Ireland;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Belgium;B ...
2	EUCTR2017-004279-30-NL (EUCTR)	23/01/2020	16/05/2018	A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with ...	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenonein Pa ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;France;Spain;Belgium;Austria;Israel;Germany;Netherlands;United Kingdom;Switzerland;Ita ...
3	EUCTR2017-004279-30-AT (EUCTR)	15/02/2019	04/01/2019	A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with ...	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenonein Pa ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;France;Spain;Belgium;Austria;Israel;Netherlands;Germany;United Kingdom;Switzerland;Ita ...
4	EUCTR2017-004279-30-ES (EUCTR)	21/12/2018	16/11/2018	A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with ...	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenonein Pa ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;France;Belgium;Spain;Austria;Israel;Netherlands;Germany;United Kingdom;Switzerland;Ita ...
5	EUCTR2016-000602-10-HU (EUCTR)	18/12/2018	05/11/2018	A clinical study to assess how effective and safe is idebenonetreatment in patients with Duchenne Mu ...	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and To ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;Spain;Ireland;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Belgium;B ...
6	EUCTR2017-004279-30-GB (EUCTR)	26/10/2018	09/05/2018	A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with ...	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenonein Pa ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;France;Spain;Belgium;Austria;Israel;Netherlands;Germany;Switzerland;Italy;United Kingd ...
7	EUCTR2017-004279-30-IT (EUCTR)	29/08/2018	22/01/2021	A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with ...	A Phase III Open-Label Extension Study to Assess the Long-Term Safetyand Efficacy of Idebenonein Pat ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone Product Code: [Idebenone] INN or Proposed INN: IDEBENONE	SANTHERA PHARMACEUTICALS	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	France;United States;Spain;Belgium;Austria;Israel;Netherlands;Germany;United Kingdom;Switzerland;Ita ...
8	NCT03603288 (ClinicalTrials.gov)	July 4, 2018	31/5/2018	Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenonein Pa ...	Duchenne Muscular Dystrophy	Drug: idebenone 150 mg film-coated tablets	Santhera Pharmaceuticals	NULL	Terminated	11 Years	N/A	Male	161	Phase 3	United States;Austria;Belgium;France;Germany;Italy;Spain;Switzerland;United Kingdom
9	EUCTR2017-004279-30-BE (EUCTR)	14/06/2018	04/05/2018	A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with ...	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenonein Pa ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;France;Spain;Belgium;Austria;Israel;Netherlands;Germany;United Kingdom;Switzerland;Ita ...
10	EUCTR2016-000602-10-NL (EUCTR)	26/04/2017	20/09/2016	A clinical study to assess how effective and safe is idebenonetreatment in patients with Duchenne Mu ...	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and To ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Trade Name: Raxone Product Name: Idebenone INN or Proposed INN: IDEBENONE Other descriptive name: IDEBE ...	Santhera Pharmaceuticals (Switzerland) Limited	NULL	Not Recruiting			Female: no Male: yes	266	Phase 3	United States;Spain;Ireland;Austria;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Belgium;B ...

First Previous1 2 3 4Next Last

先頭へ

302. レーベル遺伝性視神経症

臨床試験数 : 23 / 薬物数 : 15 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 33

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000017939	2013/10/01	20/06/2015	Multicenter study of therapeutic effects of Idebenonein patients with Leber hereditary optic neuropa ...	Multicenter study of therapeutic effects of Idebenonein patients with Leber hereditary optic neuropa ...	Leber hereditary optic neuropathy	1. Clinical trial medicine: Idebenone900mg/day 2. Objectives: 50 patients with LHON 3. Exclusion crit ...	Hyogo College of Medicine	Kitasato UniversityJikei University School of MedicineTokyo Medical University	Complete: follow-up complete	10years-old	80years-old	Male and Female	50	Phase 1,2	Japan

First Previous1Next Last

先頭へ